(19) World Intellectual Property Organization International Bureau

(43) International Publication Date 1 February 2001 (01.02.2001)

(10) International Publication Number WO 01/07507 A1

(51) International Patent Classification7: C08L 5/00, A61K 9/48

C08J 5/18,

des Americans, F-68000 Colmar (FR). HE, Xiongwei

(21) International Application Number:

PCT/EP00/06843

(22) International Filing Date:

18 July 2000 (18.07.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

99401849.7 00401333.0

22 July 1999 (22.07.1999) EP 16 May 2000 (16.05.2000)

(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCOTT, Robert [GB/BE]; Königin Elisabethplein 26, bus 4, B-9100 Sint Niklaas (BE). CADE, Dominique [FR/FR]; 11, rue [CN/FR]; 3, rue du Jura, F-68280 Andolsheim (FR).

(74) Agents: MANSMANN, Ivo et al.; Gödecke AG, Patents, Mooswaldallee 1, D-79090 Freiburg (DE).

(81) Designated States (national): CA, CN, ID, JP, KR, MX, US.

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).


Published:

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PULLULAN FILM COMPOSITIONS



(57) Abstract: The invention concerns compositions based on pullulan and a setting system for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules. The composition preferably further contains a surfactant. By using aqueous solution of the inventive compositions, the hard pullulan capsules are produced by a conventional dipping moulding process under the same process condition range than conventional gelatine capsules.



Pullulan Film Compositions

The invention concerns pullulan compositions for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules.

5

10

15

20

25

30

Conventional hard capsules are made with gelatine by dip moulding process. The dip molding process is based on the setting ability of hot gelatine solutions by cooling. For industrial manufacture of pharmaceutical capsules gelatine is most preferred for its gelling, film forming and surface active properties. The manufacture of hard gelatine capsules by dip moulding process exploits fully its gelling and film forming abilities. A typical dip moulding process comprises the steps of dipping mould pins into a hot solution of gelatine, removing the pins from the gelatine solution, allowing the gelatine solution attached on pins to set by cooling, drying and stripping the soformed shells from the pins. The setting of the solution on the mould pins after dipping is the critical step to obtain a uniform thickness of the capsule shell.

On a totally automatic industrial hard gelatine capsule machine, the process consists to dip mould pins into hot gelatine solution, to remove the pins from the solution, to turn the pins from downside to upside, to dry the gelatine solution (gel) attached on the pins, to strip the capsule shell and finally to cut and pre-joint the cap and body. The immediate setting of the gelatine solution on the dip pins after dipping is the key step in the process. Otherwise, the gelatine solution would flow down, leading

10

25

30

to a very low top thickness, and no capsule of quality could be produced.

Attempts have been made to manufacture capsules with materials other than gelatine, notably with modified cellulose. Successful industrial examples are the capsules made of hydroxypropyl methylcellulose (HPMC).

Pullulan is a natural, viscous polysaccharide extracellularly produced by growing certain yeasts on starch syrups. It has good film forming properties and a particularly low oxygen permeability. Its existence was reported for the first time in 1938. Hayashibara Company started the commercial production in 1976.

There are numerous patents about the use of pullulan in moulded articles, edible films, and coatings.

US 4,623,394 describes a molded article which exhibits a controlled desintegrability under hydrous conditions. The composition of the molded article consists essentially of a combination of pullulan and a heteromannan, the amount of heteromannan being, based on the dry solids, 1 to 100% of the pullulan.

JP5-65222-A describes a soft capsule, capable of stabilizing a readily oxidizable substance enclosed therein, exhibiting easy solubility, and being able to withstand a punching production method. The soft capsule is obtained by blending a capsule film substrate such as gelatin, agar, or carrageenan with pullulan.

US-3,784,390-A, corresponding to FR 2,147,112 and GB 1,374,199, discloses that certain mixtures of pullulan with at least one member of the group consisting of amylose, polyvinyl alcohol, and gelatine can be shaped by

3

compression molding or extrusion at elevated temperatures or by evaporation of water from its aqueous solutions to form shaped bodies, such as films or coatings. To retain the valuable properties of pullulan to an important extent the mixture should not contain more than 120 percent amylose, 100 percent polyvinyl alcohol, and/or 150 percent gelantine based on the weight of the pullulan in the mixture.

5

20

25

30

US 4,562,020, discloses a continuous process for producing a self-supporting glucan film, comprising casting an aqueous glucan solution on the surface of a corona-treated endless heat-resistant plastic belt, drying the glucan solution thereon while heating and releasing the resultant self-supporting glucan film. Suitable glucans are those which substantially consist of repeating maltotriose units, such as pullulan or elsinan.

JP-60084215-A2 discloses a film coating composition for a solid pharmaceutical having improved adhesive properties on the solid agent. The film is obtained by incorporating pullulan with a film coating base material such as methylcellulose.

JP-2000205-A2 discloses a perfume-containing coating for a soft capsule. The coating is obtained by adding a polyhydric alcohol to a pullulan solution containing an oily perfume and a surfactant such as a sugar ester having a high HLB.

US 2,949,397 describes a method of making a mineral filled paper which comprises the step of coating finely divided mineral filler particles with an aqueous colloidal dispersion of plant mucilage in the form of substituted mannan selected from the group consisting of manno-glactans and gluco-glactans.

4

US 3,871,892 describes the preparation of pullulan esters by the reaction of pullulan with aliphatic or aromatic fatty acids or their derivatives in the presence of suitable solvents and/or catalysers. The pullulan esters can be shaped by compression molding or extrusion at elevated temperatures or by evaporation of solvents from their solutions to form shaped bodies such as films or coatings.

US 3,873,333 discloses adhesives or pastes prepared by dissolving or dispersing uniformly a pullulan ester and/or ether in water or in a mixture of water and acetone in an amount between 5 percent to 40 percent of the solvent.

US 3,932,192 describes a paper coating material containing pullulan and a pigment.

- US 4,257,816 discloses a novel blend of algin, TKP, and guar gum which are useful in commercial gum applications, particularly for the paper-industry, where thickening, suspending, emulsifying, stabilizing, film-forming and gelforming are needed.
- US 3,997,703 discloses a multilayered molded plastic having 20 at least one layer comprising pullulan and at least one layer selected from the group consisting of layers composed of homopolymers and copolymers of olefins and/or vinyl compounds. polyesters, polyamides, celluloses, 25 polyvinylalcohol, rubber hydrochlorides, paper, and aluminum foil.

GB 1,533,301 describes a method of improving the water-resistance of pullulan by the addition of a water-soluble dialdehyde polysaccharides to pullulan.

10

25

30

GB 1559 644 also describes a method of improving the water-resistance of pullulan articles. The improved articles are manufactured by means of a process comprising bringing a mixture or shaped composition of a (a) pullulan or a water soluble derivative thereof and (b) polyuronide or a water-soluble salt thereof in contact with an aqueous and/or alcoholic solution of a di- or polyvalent metallic ion.

Although capsules were mentioned or claimed in these patents, their compositions do not have sufficient setting ability or none at all. Consequently, these compositions do not allow an industrial scale hard capsule production, and no attempt has been described to produce pullulan hard capsules by means of conventional dipping moulding processes.

Another problem with conventional pullulan hard capsules is their poor surface gliding performance, which leads to a high opening force of the pre-joint capsules and a high closing force. Indeed, these are two key parameters for a good filling performance on automatic high speed capsule filling equipment. During the filling process, the filling equipment opens, fills and recloses the capsules in an extremely high cadence. High opening or closing force can lead to defects such as non open, punched capsule ends and etc, and consequently to frequent machine stops.

The object of the present invention is therefore the provision of improved pullulan compositions which overcome the drawbacks of the prior art compositions. This object is solved according to the film forming composition, the container for unit dosage, the caplets, the capsules, the aqueous solutions, the use of the aqueous solutions for the manufacturing of hard capsules in a dip molding process, and the manufacturing of hard capsules from aqueous pullulan solutions according to the independent claims.

Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description and the drawings. The claims are to be understood as a first non-limiting approach to define the invention in general terms.

The invention provides a film-forming composition comprising pullulan and a setting system.

Surprisingly, we found that the addition of a very small amount of a setting system, preferably comprising hydrocolloids acting as a gelling agent, most preferably polysaccharides, confers an appropriate setting ability with cooling to pullulan solution so that the production of hard pullulan capsules can be produced with a conventional dip moulding process.

- In a preferred embodiment, the film forming composition may preferably further contain a cation containing salt, comprising at least one cation. Optionally, the film forming composition may further comprise at least one sequestering agent.
- In an aspect of the present invention the film compositions are used for the manufacturing of hard capsules by conventional dip moulding process as normally used in the production of conventional hard gelatine capsules.
- In an additional aspect of the present invention there are provided aqueous solutions comprising the film forming compositions of the present invention for the manufacture of capsules. The setting system gets the solution to set on the dipped pins, thus assuring a uniform capsule shell thickness. The setting system is preferably composed of a gelling agent, such as said hydrocolloids or

7

polysaccharides, and optionally salt and sequestering agent.

The cation containing salt in the composition serves to enhance the setting ability of the gelling Preferably, the salt comprises cations such as K⁺, Li⁺, Na⁺, Ca²⁺, or Mg²⁺, etc. The amount of cations preferably less than 3%, especially 0.01 to 1% by weight in aqueous pullulan solution. The preferred concentration in the solution is less than 2%.

5

20

25

In a further aspect of the present invention there are provided compositions for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules and wherein the pullulan compositions has in aqueous solution a sufficient setting ability.

In a particular aspect of the present invention there are provided containers for unit dosage forms for agrochemicals, seeds, herbs. foodstuffs, dyestuffs, pharmaceuticals, or flavoring agents produced from the film forming compositions of the present invention. Preferably, such containers are capsules, especially pharmaceutical capsules. The capsule halves of the capsules are preferably sealed with one or more layers of the film forming compositions of the present invention. The capsule halves are preferably sealed by means of a liquid fusion process. capsules of the present invention may preferably release they the product are filled with at low temperatures, preferably at room temperature.

In a further aspect of the present invention there are provided caplets encapsulated in a film forming composition of the present invention.

Compared to gelatine or HPMC, the advantages of pullulan can be mentioned as follows:

• Non-animal origin

10

25

- No chemical modification, totally natural.
- Higher product quality consistency by the fermentation process control.
 - High homogeneity and transparency of films
 - Very low oxygen permeability. Its capsules are particularly useful for the filling of oxygen sensitive products such as fish and vegetable oils.
 - · Relatively low water content, lower than gelatine.
 - High stability of various properties over storage such as mechanical and dissolution properties.

The addition of a setting system, preferably based 15 polysaccharides, to pullulan solutions enables the adaptation of specific and desired gelling properties for the production of hard pullulan capsules by a conventional dipping process. For the production of such capsules it is extremely important that the film forming pullulan solution 20 remaining on the mould pins after dipping is prohibited from flowing down the pins. Otherwise the obtained film will not have the desired uniform thickness.

Consequently the present invention enables that the hard pullulan capsules can be produced with the same equipment used for the production of conventional hard gelatine capsules in the same range of process conditions. Furthermore capsules produced from compositions of the

30

present invention have the same dimensional specifications and allow the use of the existing filling machinery and do not require specific and new equipment for the filling process.

- In an preferred embodiment of the present invention, the concentration of pullulan in the dipping aqueous solution is in a range of 10 to 60%, preferably 10 to 50%, more preferably 15 to 40%, and most preferably 10 to 40% by weight.
- Although pullulan of various molecular weight is usable, pullulan has a viscosity from 100 cps to 2000 cps at above mentioned concentration and at dipping temperature (40-70°C) is preferred.
- The pullulan without desalting (Japanese food grade) is usable, however the desalted pullulan (Japanese pharmaceutical excipients grade) is preferable for its improved mechanical properties.

In preferred embodiments of the present invention the setting system comprises a hydrocolloid or mixtures of hydrocolloids.

Suitable hydrocolloids or mixtures thereof for the present invention. producing synergistic properties, from the group comprising natural seaweeds, natural seed gums, natural plant exudates, natural fruit biosynthetic gums, gelatines, biosynthetic processed starch or cellulosic materials, preferred are the polysaccharides.

In a preferred embodiment of the present invention, the polysaccharides are selected from the group comprising alginates, agar gum, guar gum, locust bean gum (carob),

carrageenan, tara gum, gum arabic, ghatti gum, Khaya grandifolia gum, tragacanth gum, karaya gum, pectin, arabian (araban), xanthan, gellan, starch, Konjac mannan, galactomannan, funoran, and other exocellular polysaccharides. Preferred are exocellular polysaccharides.

Preferred exocellular polysaccharides for use in the present invention are selected from the group comprising xanthan, acetan, gellan, welan, rhamsan, furcelleran, succinoglycan, scleroglycan, schizophyllan, tamarind gum, curdlan, and dextran.

In a further preferred embodiment of the present invention the hydrocolloids of the setting system are kappacarrageenan or gellan gum or combinations like xanthan with locust bean gum or xanthan with konjac mannan.

- Among the setting systems mentioned above, the systems of kappa-carrageenan with cations and gellan gum with cations are specifically preferred. They produce high gel strength at low concentrations and have good compatibility with pullulan.
- The amount of the setting agent is preferably in the range of 0.01 to 5% by weight and especially preferred 0.03 to 1.0% in the aqueous pullulan solution of the present invention.
- In a further preferred embodiment of the present invention
 the sequestering agents are selected from the group
 comprising ethylenediaminetetraacetic acid, acetic acid,
 boric acid, citric acid, edetic acid, gluconic acid, lactic
 acid, phosphoric acid, tartaric acid, or salts thereof,
 methaphosphates, dihydroxyethylglycine, lecithin or beta
 cyclodextrin and combinations thereof. Especially preferred

10

is ethylenediaminetetraacetic acid or salts thereof or citric acid or salts thereof.

In another preferred embodiment of the present invention, the amount of the sequestering agent is preferably less than 3%, especially 0.01 to 1% by weight of the aqueous dipping solution.

In the case that gellan is used as gelling agent, the compositions preferably contain a sequestering agent to improve the capsule solubility. The preferred sequestering agents are ethylenediaminetetraacetic acid or salts thereof and citric acid and salts thereof. The amount is preferably less than 1% in the solution compositions.

The pullulan compositions of the present invention may in a further preferred embodiment additionally 15 pharmaceutically or food acceptable colouring agents in the range of from 0% to 10% based upon the weight of the film. The colouring agents may be selected from the group comprising azo-, quinophthalone-, triphenylmethane-, xanthene- or indigoid dyes, iron oxides or hydroxides, titanium dioxide or natural dyes or mixtures thereof. 20 Examples are patent blue V, acid brilliant green BS, red 2G, azorubine, ponceau 4R, amaranth, D+C red 33, D+C red 22, D+C red 26, D+C red 28, D+C yellow 10, yellow 2 G, FD+C yellow 5, FD+C yellow 6, FD+C red 3, FD+C red 40, FD+C blue 25 1, FD+C blue 2, FD+C green 3, brilliant black BN, carbon black, iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, riboflavin, carotenes, anthocyanines, turmeric, cochineal extract, clorophyllin, canthaxanthin, caramel, or betanin.

30 The inventive pullulan compositions may in a further preferred embodiment additionally contain at least one

12

pharmaceutically or food acceptable plasticiser or flavoring agent.

yet another preferred embodiment of the invention the pullulan containers, such as capsules may be coated with a suitable coating agent like cellulose acetate phthalate, polyvinyl acetate phthalate, methacrylic acid gelatines, hypromellose phthalate, hydroxypropylmethyl cellulose phthalate, hydroxyalkyl methyl cellulose phthalates, hydroxypropyl methylcellulose acetate succinate or mixtures thereof to provide e.g. enteric properties.

10

15

20

25

30

In a preferred embodiment of the present invention, the film-forming compositions further comprise one or more surfactants.

The surfactant in the compositions improves the capsule surface properties in such a way that the capsule works well on the conventional automatic high speed capsule filling equipment.

We have surprisingly found that the addition of a small quantity of selected surfactants of pharmaceutical or food quality, we can improve dramatically the pullulan film surface gliding performance, consequently to get the capsule opening and closing forces to the range required by filling equipment.

Therefore, the present invention provides compositions for hard pullulan capsules with improved surface properties containing pullulan, setting system and surfactant and the aqueous solutions of said film forming compositions for the manufacturing of the capsules.

With these preferably aqueous solutions, we can produce hard pullulan capsules with good filling performance by

13

conventional dip mould process just like hard gelatine capsules.

A further percieved disadavantage of unmodified pullulan capsule film is its adhesive nature or tackiness when touched by hand. The rapid remoisturing properties of pullulan results in a percieved tackiness when holding the capsule film in the hand for 30 seconds or more.

An additional disadvantage is evident on swallowing the capsule film as the film may adhere to the tongue, palet (upper mouth), throat or oesophagus and compare unfavorably with traditional gelatin film capsules.

10

15

20

25

30

Patient compliance is a major advantage of the traditional hard gelatin capsule and supported by several market studies which cite "ease of swallow" as an important factor in patient preference for the capsule oral dosage form.

In order to solve this percieved disadvantage of pullulan capsule film, surprisingly it has been found that a surfactant content in the pullulan capsule film provides an acceptable temporary water-repellant surface for handling or swallowing the capsule. Additionally, the selected surfactant may be applied externally as a transparent coating in the range 0.5 to 100 microns. The selected surfactants are water soluble at 37C.

The pullulan in the compositions is the base material for hard capsule making. Its preferred concentration in the aqueous solutions comprising the surfactant is from 10 to 40%.

The preferred gelling agents for the use with the surfactant are kappa-carrageenan and gellan with a concentration in the solutions 0.05-3%.

The surfactant in the compositions is aimed to improve the capsule surface gliding performance, and so the capsule filling performance on filling equipment. The surfactant can be cationic, anionic, non-ionic or amphoteric, preferably selected from pharmaceutical and food quality such as sodium lauryl sulphate (SLS), dioctyl sulfosuccinate (DSS), benzalkonium chloride, benzethonium chloride, cetrimide (trimethyltetradecylammonium bromide), fatty acid sugar esters, glyceryl monooleate, polyoxyethylene sorbitan fatty acid esters, polyvinyl alcohol, dimethylpolysiloxan, sorbitan esters or lecithin. Its amount based on pullulan is preferably 0.01% to 3%.

The above mentioned and other features of the present invention will be better understood by reference to the following examples and the accompanying figure, in which:

Fig. 1 shows a graph listing dissolution test results of capsules according to the present invention filled with acetaminophen in deionized water at 37°C (USP XXIII dissolution).

The following examples and tests, not limitative, demonstrate the pullulan capsule production and properties. Furthermore, the examples demonstrate the hard capsule making, the surface gliding improvement, and the capsule filling improvement.

25 Example 1:

10

15

30

1.0 kg of pullulan (PI-20, Japanese Pharmaceutical Excipients grade) powder is mixed with 10 g of kappa-carrageenan. To 4.0 kg of deionised water under stirring at room temperature is added 20 g of potassium acetate (0.2% by weight in the solution), followed by addition of the above mixture (20% of pullulan and 0.2% of carrageenan in

15

the solution). The powder addition and stirring speeds should be very high in order to avoid the forming of lumps, which take a long time to be dissolved. The solution is heated up to 70°C under stirring to totally dissolve the carrageenan and pullulan. It is possible to dissolve the components directly at 70°C, but the tendency of pullulan to lump is much higher.

The pullulan solution thus prepared is defoamed under slow stirring and then poured into a dipping dish of a pilot machine of conventional hard gelatine capsule production equipment. While keeping the dipping pullulan solution at 60°C, natural transparent hard pullulan capsules of size 0 were produced according to the conventional process with the same dimensional specifications to the conventional hard gelatine capsules.

Example 2:

10

15

20

25

30

1.0 kg of pullulan (PI-20) powder is mixed with 6 g of gellan. To 4.0 kg of deionised water under stirring at room temperature is added 20 g of potassium acetate (0.4% by weight in the solution) and 2 g of ethylenediaminetetraacetic acid disodium salt (0.04% in the solution), followed by addition of the above mixture (20% of pullulan and 0.12% of gellan in the solution). Heat the solution up to 75°C under stirring to dissolve totally the gellan and pullulan.

The pullulan solution thus prepared is defoamed under slow stirring and then poured into a dipping dish of a pilot machine of conventional hard gelatine capsule production equipment. While keeping the dipping pullulan solution at 60°C, natural transparent hard capsules of size 0 were produced according to the conventional process with the

same dimensional specifications to the conventional hard gelatine capsules.

Disintegration test results:

Table 1: Disintegration test results (according to USP XXIII 1995-<701> Disintegration):

Capsule	Example 1	Example 2
Capsule emptied time	3.0 min	2.0 min
Total disintegration time	10.0 min	11.8 min

Dissolution test results of capsules filled with acetaminophen in deionised water at 37°C (USP XXIII dissolution) are represented in Fig. 1.

10 Example 3: Pullulan film gliding improvement

In 400g of demineralised water at room temperature were dispersed under stirring 0.05 g SLS (500ppm/pullulan), 1 g of kappa-carrageenan (0.2%), 1.25 g of potassium acetate (0.25%) and 100 g of pullulan (20%). The mixture is heated to 70°C under stirring for complete solubilisation and then the stirring is reduced for defoaming. The solution then is used to cast on glass plates of 4 mm thickness to form pullulan films of about 100 μ m thickness after drying at room conditions.

The pullulan film gliding performance is evaluated by a test on a slanted plan, a method commonly used by gelatine producers. The method determines the smallest angle of inclination of glass plate to provoke the gliding of a film coated glass plate over another one with films face to

WO 01/07507

face. Consequently, the smaller the gliding angle, the better the film gliding performance.

Repeat the above example with surfactant contents listed in Table 2.

In Table 2, we gathered the gliding performance for different surfactants and quantity.

Surfactant	No	500 ppm	1000 ppm	5000 ppm
SLS		9	5	6
	29			
Hydrolysed deoil lecithin		9	9	7
Polysorbate 20		12	12	· · · · · · · · · · · · · · · · · · ·
Polysorbate 80		10	9	
Sorbitan laurate		10	8	
Sorbitan oleate		9	7	

Table 2: Pullulan gliding performance (°)

Example 4: Pullulan capsule production and performance

In 142 liters of demineralised water at room temperature were dispersed under stirring 20 g hydrolysed deoil lecithin (500ppm/pullulan), 363 g kappa-carrageenan (0.2%) and 40 kg pullulan (22%). The mixture is heated up to 70°C under stirring for total solubilisation. 455 g potassium acetate previously dissolved in some water was then added into the solution. A slurry made with 800 g TiO₂, 3 litres hot water and 3 liters so prepared pullulan solution by high shearing was added into the solution in order to produce white opaque capsules. After defoaming, the solution is finally stabled at 60°C.

10

A second identical preparation was made. The two preparations were used to feed a conventional hard gelatine capsule production machine, white opaque hard pullulan capsules were then produced in the similar way to hard gelatine capsules.

As reference, transparent pullulan hard capsules without surfactant in the formulation were produced in the same way as above.

The improvement of hard pullulan capsules by the addition of surfactant is illustrated by the data gathered in Table 3, and was confirmed by a filling trial on a filling equipment KGF400.

Table 3

Capsule	Opening force of pre- lock capsule	Closing force
Capsule of example 2	12 g	6.0 N
Reference capsule	36 g	7.6 N

<u>Claims</u>

- 1. A film forming composition comprising pullulan and a setting system.
- The film forming composition according to claim 1, wherein the setting system further comprises cations.
 - 3. The film forming composition according to claim 2, wherein the cations are preferably selected from the group comprising K⁺, Na⁺, Li⁺, NH4⁺, Ca⁺⁺ and Mg⁺⁺.
- The film forming compositions according to claims 1 or
 2, wherein the setting system further comprises at least one sequestering agent.
 - 5. The film forming composition according to claim 4, wherein the at least one sequestering agent is selected from the group comprising ethylenediaminetetraacetic acid, acetic acid, boric acid, citric acid, edetic acid, gluconic acid, lactic acid, phosphoric acid, tartaric acid, or salts thereof, methaphosphates, dihydroxyethylglycine, lecithin or beta cyclodextrin.
- 6. The film forming composition according to any one of claims 1 to 5, wherein the setting system comprises hydrocolloids.
 - 7. The film forming composition according to claim 6, wherein the hydrocolloids of the setting system are selected from polysaccharides.
- 25 8. The film forming composition according to one of claims 6 or 7, wherein the hydrocolloids of the setting system are selected from exocellular polysaccharides.

- 9. The film forming composition according to any one of the preceding claims, wherein the content of pullulan is 85% to 95% by weight, and wherein the content of water is 5% to 15% by weight.
- 10. The film forming composition according to any one of the preceding claims, wherein the content of the cations is less than 5% by weight, preferably 0.01% to 3% by weight, more preferably 0.5% to 2% by weight.
 - 11. The film forming composition according to any one of the preceding claims, wherein the content of the sequestering agent is less than 5% by weight, preferably 0.01% to 3% by weight, more preferably 0.5% to 2% by weight.
- 12. The film forming composition according to any one of claims 6 to 11, wherein the hydrocolloids of the setting system are selected from the group comprising alginates, agar gum, guar gum, locust bean gum (carob), carrageenan, tara gum, gum arabic, ghatti gum, Khaya grandifolia gum, tragacanth gum, karaya gum, pectin, arabian (araban), xanthan, gellan, starch, Konjac mannan, galactomannan, or funoran.
 - 13. The film forming composition according to any one of claims 6 to 11, wherein the hydrocolloids of the setting system are selected from the group comprising xanthan, acetan, gellan, welan, rhamsan, furcelleran, succinoglycan, scleroglycan, schizophyllan, tamarind gum, curdlan, or dextran.
- 14. The film forming composition according to any one of claims 6 to 11, wherein the hydrocolloids of the setting system are selected from gellan gum or kappacarrageenan.

15. The film forming composition according to any one of claims 1 to 14, further containing plasticizers or/and flavoring agents.

21

16. The film forming composition according to claims 1 to 15, further containing colouring agents in a range from about 0% to 10% based upon the weight of the composition.

5

10

15

20

- 17. The film forming composition according to claim 16 wherein the colouring agent or mixture of colouring agents is selected from the group comprising azo-, quinophthalone-, triphenylmethane-, xanthene- or indigoid dyes, iron oxides or hydroxides, titanium dioxide or natural dyes.
- 18. The film forming composition according to claim 17 wherein the colouring agent or mixture of colouring agents is selected from the group comprising patent blue V, acid brilliant green BS, red 2G, azorubine, ponceau 4R, amaranth, D+C red 33, D+C red 22, D+C red 26, D+C red 28, D+C yellow 10, yellow 2 G, FD+C yellow 5, FD+C yellow 6, FD+C red 3, FD+C red 40, FD+C blue 1, FD+C blue 2, FD+C green 3, or brilliant black BN.
 - 19. The film forming composition according to claim 16 wherein the colouring agent or mixture of colouring agents is selected from the group comprising carbon black, iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, riboflavin, carotenes, anthocyanines, turmeric, cochineal extract, clorophyllin, canthaxanthin, caramel, or betanin.
- 20. The film forming composition according to any one of the preceding claims, wherein the composition comprises one or more surfactants.

15

- 21. The film forming composition according to claim 20, wherein the surfactant is selected from the group comprising sodium lauryl sulphate (SLS), dioctyl sodium sulfosuccinate (DSS), benzalkonium benzethonium chloride, cetrimide (trimethyltetradecylammonium bromide), fatty acid sugar esters, glyceryl monooleate, polyoxyethylene sorbitan acid esters, polyvinyl alcohol, dimethylpolysiloxan, sorbitan esters or lecithin.
- 10 22. The film forming composition according to any one of claims 20 or 21, wherein the content of surfactant is 0.01 to 3% by weight related to the amount of pullulan.
 - 23. Container for unit dosage forms for agrochemicals, seeds, herbs, foodstuffs, dyestuffs, pharmaceuticals, or flavouring agents produced from the film forming composition according to any one of claims 1 to 22.
 - 24. Container according to claim 23 which is a capsule, preferably a pharmaceutical capsule.
- 25. Container according to claim 23 or 24, wherein the container comprises a coating.
 - 26. Container according to claim 25, wherein the coating is selected from the group comprising cellulose acetate phthalate, polyvinyl acetate phthalate, methacrylic acid gelatines, hypromellose phthalate, hydroxypropylmethyl cellulose phthalate hydroxyalkyl methyl cellulose phthalates, hydroxypropyl methylcellulose acetate succinate or mixtures thereof.
 - 27. Container according to claim 25, wherein the coating is a surfactant.

PCT/EP00/06843

5

10


15

- 28. Container according to claim 27, wherein the coating is in the range of 0.5 to 100 microns.
- 29. Container according to claims 27 or 28, wherein the surfactant is selected from the group comprising sodium lauryl sulphate (SLS), dioctyl sodium sulfosuccinate (DSS), benzalkonium chloride, benzethonium chloride, cetrimide (trimethyltetradecylammonium bromide), fatty acid sugar esters, glyceryl monocleate, polyoxyethylene sorbitan fatty acid esters, polyvinyl alcohol, dimethylpolysiloxan, sorbitan esters or lecithin.
- 30. A caplet encapsulated in a film forming composition according to one of claims 1 to 21.
- 31. Container comprising two halves forming a capsule, wherein the the container is sealed with one or more layers of the composition according to claims 1 to 22.
- 32. Container according to claim 31 wherein the capsule halves are sealed by a liquid fusion process.
- 33. Container according to claim 30 or 32, wherein the capsule is a container according to one of claims 23 to 25.
- 34. Container according to any one of claims 23 to 33 wherein a product filled in the container is releasable at a low temperature such as at room temperature.
- 35. An aqueous solution of the film forming composition according to any one of claims 1 to 22 for the manufacturing of capsules.

- 36. The aqueous solutions according to claim 35, comprising pullulan in an amount of 10 to 60%, preferably 15 to 40% by weight of the aqueous solution.
- 37. The aqueous solution according to claim 35 or 36, comprising setting agent in an amount of 0.01 to 5%, preferably 0.03 to 1.0% by weight of the aqueous solution.
- 38. The aqueous solution according to any one of claims 35 to 37, further comprising cations in an amount less than 3%, preferably 0.01 to 1% by weight of the aqueous solution.
 - 39. The aqueous solution according to any one of claims 35 to 38, further comprising sequestering agents in an amount less than 3%, preferably 0.01 to 1% by weight of the aqueous solution.
 - 40. Use of the aqueous solution according to any one of claims 35 to 39 for the manufacturing of hard capsules in a dip moulding process.
- 41. Manufacturing of hard capsules from the aqueous pullulan solution according to any one of claims 35 to 39 in a dip moulding process with conventional hard gelatine capsules process parameters and equipment.

1/1

FIG. 1



INTERNATIONAL SEARCH REPORT

Interna ial Application No PCT/EP 00/06843

According to International Patent Classification (IPC) or to both national classification and IPC S. FILES SEARCHED TIPC 7 COBJ COBL AG1K Documentation searched classification system followed by classification symbols) Documentation searched content than minimum documentation to the entent that such documents are included in the flexible searched Electronic data base consided during the international search (name of data base and, where practical, search ferms used) WPT Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Castion of document, with indication, where appropriate, of the netward passages Recording to data has been consided during the international search (name of data base and, where practical, search ferms used) WPT Data, PAJ DATABASE WPT Meek 197833 Derwent Publications Ltd., London, GB; AN 1978-59705A XPO02152902 X JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract & CIEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Ohio, US; abstract no. 147859, ab	A CLASSI	FICATION OF SUBJECT MATTER		
S. PELOS SEARCHED		C08J5/18 C08L5/00 A61K9/4	8	
S. PELOS SEARCHED				
S. PELOS SEARCHED	A coording to	Laterational Patent Classification (IPC) or to both national classific	ention and IDC	
Documentation searched (desaptication system belowed by desaltication symbols)	·		cation and IFO	
Documentation searched other than minimum documentation to the extent that such documents are included in the flekts searched Electronic data base considered during the international search (name of data base and, where practical, search terms user) WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Catation of document, with indication, where appropriate, of the relevant passages Relevant to daim No. X DATABASE WPI Week 197833 Derwent Publications Ltd., London, 6B; AN 1978-59705A XP002.152902 A JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract A CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986-11-18) example 3; table I -/ X Patient family members are listed in annex. To advantage the present state of the art which is not considered to be of particular reference or printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but of printy date and not in conflict with the application but o			tion symbols)	
Electronic data base considered during the international search (name of data base and, where practical, search terms used) WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Castopon* Castion of document, with incication, where appropriate, of the relevant passages Relevant to claim No. X DATABASE WPI Week 197833 Derwent Publications Ltd., London, GB; AN 1978-59705A XP002152902 & JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Onlio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986-11-18) example 3; table I -/ X Petent tamily members are listed in annex. **Special categories of cited documents: **A document defining the general state of the art which is not considered to be cipartical reversione **Of content defining the general state of the art which is not considered to be cipartical reversione **Of content defining the general state of the art which is not considered refere special research is specified on the research responsibility of the international search 15 November 2000 Name and malling address of the ISA European Patent Clibia, P.B. 5618 Patentian 2 Tel (437-70) 340-2404, Tr. 31 6518 pp.nn.	IPC 7	COBJ COBL A61K		
Electronic data base considered during the international search (name of data base and, where practical, search terms used) WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Castopon* Castion of document, with incication, where appropriate, of the relevant passages Relevant to claim No. X DATABASE WPI Week 197833 Derwent Publications Ltd., London, GB; AN 1978-59705A XP002152902 & JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Onlio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986-11-18) example 3; table I -/ X Petent tamily members are listed in annex. **Special categories of cited documents: **A document defining the general state of the art which is not considered to be cipartical reversione **Of content defining the general state of the art which is not considered to be cipartical reversione **Of content defining the general state of the art which is not considered refere special research is specified on the research responsibility of the international search 15 November 2000 Name and malling address of the ISA European Patent Clibia, P.B. 5618 Patentian 2 Tel (437-70) 340-2404, Tr. 31 6518 pp.nn.				
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of occument, with indication, where appropriate, of the relevant passages Relevant to claim No. X	Documental	ion searched other than minimum documentation to the extent that	such documents are included in the fields s	earched
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of occument, with indication, where appropriate, of the relevant passages Relevant to claim No. X				
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of occument, with indication, where appropriate, of the relevant passages Relevant to claim No. X	Electronic d	ata base consulted during the international search (name of data base	ase and, where practical, search terms used	<u>.</u>
C. DOCUMENTS CONSIDERED TO BE RELEVANT Catogory* Citation of document, with indication. where appropriate, of the relevant passages Petevant to claim No. I DATABASE WPI Week 197833 Derwent Publications Ltd., London, GB; AN 1978-59705A XPO02152902 8 JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract 2 CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986-11-18) example 3; table I —/— X Patient family members are listed in the continuation of box C. X Patient family members are listed in annex. 1-7— X Patient family members are listed in annex. 1-7— X Patient family members are listed in annex. 1-7— 1-7— X Patient family members are listed in annex. 1-7— 1-7— X Patient family members are listed in annex. 1-7—	İ			•
Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document to claim No.	MIT Da	ta, Tho		
Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document to claim No.				
Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document, with indication, where appropriate, of the relevant passages Category* Citation of document to claim No.				
DATABASE WPI Week 197833 Derwent Publications Ltd., London, GB; AN 1978-59705A XP002152902 & JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Ohio, US; abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986-11-18) example 3; table I -/ X Patent tamily members are listed in annex. *Special categories of cited documents: *A decument bull published on or after the international filing date or protect on the continuation of box of the continuation of the protect of the publication date; the publication date; the publication date; the publication date; the or protect of the publication of the of the pu				
Meek 197833 Derwent Publications Ltd., London, GB; AN 1978–59705A XP002152902 & JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978–07-14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978–10-30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986–11–18) example 3; table I -/ X Further documents are listed in the continuation of box C. X Patent tamily members are listed in annex. *Special categories of citad documents:	Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
Meek 197833 Derwent Publications Ltd., London, GB; AN 1978–59705A XP002152902 & JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978–07-14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978–10-30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986–11–18) example 3; table I -/ X Further documents are listed in the continuation of box C. X Patent tamily members are listed in annex. *Special categories of citad documents:				
Derwent Publications Ltd., London, GB; AN 1978-59705A XP002152902 & JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Ohio, US; abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986-11-18) example 3; table I -/ X Further documents are listed in the continuation of box C. X Patent family members are listed in annex. Y Secala categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance: the considered to be of particular relevance in the continuation of the considered to be of particular relevance in the continuation of other special reason (as specified) I'- document which may throw doubts on priority claimings or which is cited to establish the publication date of another citation or other special reason (as specified) I'- document published prior to the international filling date but later than the priority date claimed I'- document published prior to the international filling date but later than the priority date claimed I'- document of other special reason (as specified) O'- document published prior to the international filling date but later than the priority date claimed I'- document of other special reason (as specified) O'- document published prior to the international filling date but later than the priority date claimed I'- document of published prior to the international filling date but later than the priority date claimed I'- document published prior to the international filling date but later than the priority date claimed I'- document published prior to the international filling date but later than the priority date claimed I'- document of published prior to the international filling date but later than the priority date claimed I'- document of published prior to the international search I'- document of published prior to the international search I'- document of published prior	X		•	1-41
AN 1978-59705A XP002152902 & JP 53 079972 A (HAYASHIBARA BIOCHEMICAL LAB), 14 July 1978 (1978-07-14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978-10-30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986-11-18) example 3; table I -/ X Petent family members are listed in annex. *Special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance. *A document defining the general state of the art which is not considered to be of particular relevance. *I document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another usibly nor other special reason (is special reason (is special reason (is special reason) (is special re			n GR•	•
* Special categories of cited documents: ** Special categories of cited documents: ** A document defining the general state of the art which is not considered to be abablish the publication date of another which is cited to stabilish the publication date of another or other means ** Occument referring to an oral disclosure, use, exhibition or other means ** Occument referring to an oral disclosure, use, exhibition or other means ** Occument referring to an oral disclosure, use, exhibition or other means ** Occument referring to an oral disclosure, use, exhibition or other means ** Occument referring to an oral disclosure, use, exhibition or other means ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published prior to the international filing date but laier than the priority date claimed ** Occument published priority d				
LAB), 14 July 1978 (1978–07–14) abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978–10–30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986–11–18) example 3; table I -/ X Patent family members are listed in annex. *Special categories of cited documents:/ *Special categories of cited documents:/ *A' document defining the general state of the art which is not considered to be of particular revenue *E' earlier document but published on or after the international filing date or priority date and not in conflict with the application but cannot be considered to be of particular revenue *Counter the principle or theory underlying the invention cannot be considered novel or cannot be considered to be or particular revenue *Counter the principle or theory underlying the invention or other special reason (as specified) *Counter the referring to a noral disclosure, use, exhibition or other special reason (as specified)				
abstract & CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978–10–30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986–11–18) example 3; table I -/ X Further documents are listed in the continuation of box C. X Patent tamily members are listed in annex. Ye patent tamily me			OCHEMICAL	
& CHEMICAL ABSTRACTS, vol. 89, no. 18, 30 October 1978 (1978–10–30) Columbus, Ohio, US; abstract no. 147859, abstract X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986–11–18) example 3; table I -/ X Patent tamily members are listed in annex. * Special categories of cited documents: *A' document disting the general state of the art which is not considered to be of particular relevance *E' earlier document but published on or after the international filing date or priority date and not in conflict with the application but clied to understand principle or there yunderlying the eneral relevance to the distribution or other special reason (as specified) *I' document therefore to an oral disclosure, use, exhibition or other special reason (as specified) *O' document referring to an oral disclosure, use, exhibition or other special reason (as specified) *O' document referring to an oral disclosure, use, exhibition or other special reason (as specified) *O' document referring to an oral disclosure, use, exhibition or other means *P document published prior to the international filling date but later than the priority date latined *Date of the actual completion of the international search 15 November 2000 Name and mailing address of the ISA European Patent Office, P.S. 5818 Patentlaan 2 NL - 2280 HV Fillipswift, Tell (431-70) 340-2040, Tx. 31 651 epp nl.				
Columbus, Ohio, US; abstract no. 147859, abstract no. 147859, abstract no. 147859, abstract X		& CHEMICAL ABSTRACTS, vol. 89, no	o. 18,	
abstract X		30 October 1978 (1978-10-30)		
A decument defining the general state of the art which is not considered to be of particular relevance: the claimed invention or other special reason (as specified) 1. document which may throw doubts on priority claim(s) or which is cled to lessablesh the published or or other means 1. document which may throw doubts on priority claim(s) or other means 1. document intermity members are listed in annex. 2. Patent tamily members are listed in annex. 2. Patent tamily members are listed in annex. 3. Patent tamily members are listed in annex. 4. Patent tamily members are listed in annex. 4. Patent tamily members are listed in annex. 4. Patent tamily members are listed in annex. 5. Patent tamily members are listed in annex. 6. Patent tamily members are listed in annex. 7. Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the international flat or priority date and not in conflict with the application or other international flat or priority date and not in conflict with the application but cited to understand the principle or priority date				
X US 4 623 394 A (SATOSHI NAKAMURA ET AL.) 18 November 1986 (1986–11–18) example 3; table I -/ * Special categories of cited documents: * Special categories of cited documents: * Italer document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to be of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is carbinated with one or more other such documents or their means of the same patent family Date of the actual completion of the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of the actual completion of the ISA European Patent Office, P.B. 5818 Patentlaan 2 N 2280 HV Rijswijk; Tel. (431–70) 340–2040, T.x. 31 651 epo ni.			. •	
Second categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance: 'E' earlier document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means of the actual completion of the international filing date but later than the priority date claimed 'P' document published prior to the international filing date but later than the priority date claimed 'Dot earlier of the actual completion of the international search 'Dot earlier of the actual completion of the international search 'Dot earlier of the actual completion of the international search 'Dot earlier of the actual completion of the international search 'Dot earlier of the actual completion of the international search				
*Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E' earlier document but published on or after the international filing date "L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O' document referring to an oral discrosure, use, exhibition or other means "P' document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 15 November 2000 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (431-70) 340-2040, Tx. 31 651 epo ni.	Х		ET AL.)	1-30
Further documents are listed in the continuation of box C. X Patent family members are listed in annex. *Special categories of cited documents: A' document defining the general state of the art which is not considered to be of particular relevance E' earlier document but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone voice and its combined with one or more other such document effect of understand in the art. *Codocument reterring to an oral disclosure, use, exhibition or other special reason (as specified) P' document epithished prior to the international filling date but later than the priority date claimed Date of the actual completion of the international search 15 November 2000 Name and malling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tet. (431-770) 340-9240, Tx. 31 651 epo ni.				
*Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *Bovement published prior to the international search *To act and the considered novel or cannot be considered to involve an inventive step when the document is taken alone or other means *To act and the principle or theory underlying the priority date and not in conflict with the application but cited to understand the principle or theory underlying the principle or theory underlying the or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. **Stream of the same patent family **Date of mailing of the international search report **Outment published prior to the international filing date but later than the priority date calimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. **Stream of the same patent family **Date of mailing of the international search report **Outment published of in the art. **Stream of the same patent family **Date of mailing address of the ISA **European Patent Office, P.B. 5818 Patentlan 2 **Null Patent Tamily members are listed in onto itself to understand the principle or theory underlying th		example 3, cable 1		
*Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "Date of the actual completion of the international search Date of the actual completion of the international search Is November 2000 Name and malling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tet (+31-70) 340-2040, Tx. 31 651 epo nl.		•	-/	
*Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "Date of the actual completion of the international search Date of the actual completion of the international search Is November 2000 Name and malling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tet (+31-70) 340-2040, Tx. 31 651 epo nl.				
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document reterring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *B* document member of the same patent family Date of the actual completion of the IsA *European Patent Office, P.B. 5818 Patentlaan 2 *NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni.	X Funt	ner documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document reterring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *B* document member of the same patent family Date of the actual completion of the IsA *European Patent Office, P.B. 5818 Patentlaan 2 *NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni.	Special ca	tegories of cited documents :		
considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report November 2000 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.			or priority date and not in conflict with	the application but
filing date *L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O' document referring to an oral disclosure, use, exhibition or other means *P' document published prior to the international filing date but later than the priority date claimed *B' document published prior to the international filing date but later than the priority date claimed *B' document published prior to the international filing date but later than the priority date claimed *B' document member of the same patent family *Date of the actual completion of the international search *B' document member of the same patent family *Date of mailing address of the ISA *European Patent Office, P.B. 5818 Patentlaan 2 *NL - 2280 HV Rijswijk *Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. *A document ment be considered novel or cannot be considered to movel or cannot be considered to movel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to movel or cannot be considered to movel or cannot be considered to movel or cannot be considered novel or cannot be considered to movel or cannot be considered novel or cannot be considered to movel or cannot be considered novel or cannot be	consid	ered to be of particular relevance	invention	
which is cited to establish the publication date of another citation or other special reason (as specified) "O' document referring to an oral disclosure, use, exhibition or other means "P' document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing address of the ISA European Patent Office, P.B. 5818 Patenttaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	filing d	ale	cannot be considered novel or cannot	be considered to
Cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. 12 November 2000 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patenttaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni.	which	is cited to establish the publication date of another	"Y" document of particular relevance; the c	laimed invention
other means 'P' document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search patent family Date of mailing of the international search patent of the same patent family Date of mailing of the international search report 15 November 2000 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	'O' docume	ent referring to an oral disclosure, use, exhibition or	cannot be considered to involve an involve an involve document is combined with one or mo	ventive step when the re other such docu-
tater than the priority date claimed *8* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 15 November 2000 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni.		··	ments, such combination being obviou	ıs to a person skilled
15 November 2000 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	later th	an the priority date claimed	*&* document member of the same patent t	amity
Name and malling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	Date of the a	actual completion of the international search	Date of mailing of the international sea	rch report
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	1!	5 November 2000	01/12/2000	
NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	Name and n	nalling address of the ISA	Authorized officer	
		NL – 2280 HV Rijswijk		
			Lensen, H	

INTERNATIONAL SEARCH REPORT

Intern .1al Application No PCT/EP 00/06843

	NAME OF THE PROPERTY OF THE PR	PCT/EP 00	/ 00040
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
X	EP 0 328 317 A (TAKEDA CHEMICAL INDUSTRIES) 16 August 1989 (1989-08-16) example 3		1,6,13, 35-37
X	PATENT ABSTRACTS OF JAPAN vol. 17, no. 232 (C-1056), 12 May 1993 (1993-05-12) & JP 04 363332 A (MITSUBISHI RAYON) abstract & DATABASE WPI Week 199305 Derwent Publications Ltd., London, GB; AN 1993-039394 abstract		1
X	PATENT ABSTRACTS OF JAPAN vol. 17, no. 376 (C-1084), 15 July 1993 (1993-07-15) & JP 05 065222 A (FUJI CAPSULE), 19 March 1993 (1993-03-19) abstract & DATABASE WPI Week 199316 Derwent Publications Ltd., London, GB; AN 129084 abstract		1-30
A	US 3 784 390 A (HIROMI HIJIYA ET AL.) 8 January 1974 (1974-01-08) cited in the application	2	
			·
	·		

INTERNATIONAL SEARCH REPORT

Intern. Ial Application No PCT/EP 00/06843

Pa	tent document		Publication		atent family	Publication
cited	in search report		date	r	nember(s)	date
JP	53079972	A	14-07-1978	NONE		
US	4623394	Α	18-11-1986	JP	1843452 C	12-05-1994
				JP	5049705 B	27-07-1993
				JP	60219238 A	01-11-1985
				FR	2562899 A	18-10-1985
				GB	2162528 A,B	05-02-1986
EP	328317	Α	16-08-1989	CN	1036967 A	08-11-1989
				JP	1289457 A	21-11-1989
JP	04363332	Α	16-12-1992	NONE		·
JP	05065222	A	19-03-1993	NONE		
US	3784390	Α	08-01-1974	JP	48051777 A	20-07-1973
				JP	52006346 B	21-02-1977
				AR	200845 A	27-12-1974
				AR	200858 A	27-12-1974
				AU	468995 B	29-01-1976
				AU	4457672 A	17-01-1974 16-11-1972
				BE CA	786574 A 1007415 A	29-03-1977
				CH	564574 A	31-07-1975
				DE	2235991 A	08-02-1973
	•			ES	405103 A	16-11-1975
				FI	54133 B	30-06-1978
				FR	2147112 A	09-03-1973
				GB	1374199 A	20-11-1974
				IT	1048891 B	20-12-1980
				NL	7210152 A,B	
				NO	138662 B	10-07-1978
	*			PH	9411 A	11-11-1975
				SE	384517 B	10-05-1976
				SU	591152 A	30-01-1978
				ZA	7205017 A	25-04-1973